Brookline Capital Management Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: Brookline Capital Management
Rating: 2.8
Author: MarketBeat

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

Company	Current Price	Rating Date	Action	Brokerage	Analyst	Rating	Price Target	Impact on Price	Details
OTLK Outlook Therapeutics	$0.41 -7.7%	1/25/2024	Upgraded by	Brookline Capital Management	Analyst K. Dolliver	Hold -> Buy	$1.57	Low	View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 1/25/2024
ONCT Oncternal Therapeutics	$9.88 +3.5%	12/4/2023	Upgraded by	Brookline Capital Management	Analyst K. Dolliver	Hold -> Buy	$40.00	Low	View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 12/4/2023
LNTH Lantheus	$56.14 +1.0%	11/30/2023	Initiated by	Brookline Capital Management	-	Buy	$100.00	Low	View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023
ANVS Annovis Bio	$10.95 +1.0%	11/10/2023	Reiterated by	Brookline Capital Management	Analyst T. Bussian	Buy	$35.00	Low	View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023
GNLX Genelux	$8.94 -4.6%	10/30/2023	Upgraded by	Brookline Capital Management	Analyst K. Dolliver	Hold -> Buy		Low	View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023
EYEN Eyenovia	$1.83 +3.1%	10/17/2023	Initiated by	Brookline Capital Management	-	Buy	$8.00	Low	View details for Brookline Capital Management rating of Eyenovia (NASDAQ:EYEN) on 10/17/2023
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
EDSA Edesa Biotech	$4.83 +3.4%	10/12/2023	Reiterated by	Brookline Capital Management	-	Buy -> Buy	$57.00	Low	View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023
OTLK Outlook Therapeutics	$0.41 -7.7%	8/30/2023	Downgraded by	Brookline Capital Management	Analyst K. Dolliver	Buy -> Hold		Low	View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/30/2023
ATBPF Antibe Therapeutics	$0.67 -6.4%	8/14/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low	View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023
ONCT Oncternal Therapeutics	$9.88 +3.5%	4/3/2023	Downgraded by	Brookline Capital Management	Analyst K. Dolliver	Buy -> Hold		Low	View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 4/3/2023
ONCT Oncternal Therapeutics	$9.88 +3.5%	3/9/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low	View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 3/9/2023
DARE Daré Bioscience	$0.35 +0.8%	2/14/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low	View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 2/14/2023
FUSN Fusion Pharmaceuticals	$11.57 +2.2%	2/13/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low	View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 2/13/2023
ECOR electroCore	$7.35 +2.9%	1/12/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A	View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023
VXRT Vaxart	$1.19 +0.8%	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low	View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022
OTLK Outlook Therapeutics	$0.41 -7.7%	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low	View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 10/3/2022
LSTA Lisata Therapeutics	$2.66 +1.9%	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low	View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022
EDSA Edesa Biotech	$4.83 +3.4%	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low	View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022
ATE Antibe Therapeutics	C$0.92 -3.2%	8/15/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A	View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 8/15/2022
ARCT Arcturus Therapeutics	$39.64 +4.6%	8/10/2022	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low	View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022
ATBPF Antibe Therapeutics	$0.67 -6.4%	6/30/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A	View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022
VERU Veru	$0.38 -7.6%	5/18/2022	Target Raised by	Brookline Capital Management	Analyst Kumaraguru Raja	Buy -> Buy	$29.00 -> $31.00	Medium	View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022
VRCA Verrica Pharmaceuticals	$5.51 +5.2%	3/10/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Medium	View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022
NTLA Intellia Therapeutics	$28.23 +2.8%	3/7/2022	Upgraded by	Brookline Capital Management	Analyst L. Cann	Hold -> Buy	$91.00	High	View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022
CRSP CRISPR Therapeutics	$70.01 +1.7%	2/14/2022	Reiterated by	Brookline Capital Management	Analyst Leah Rush	Buy	$143.00	High	View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022
NTLA Intellia Therapeutics	$28.23 +2.8%	2/14/2022	Reiterated by	Brookline Capital Management	Analyst Leah Rush	Buy		Low	View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022
CRBU Caribou Biosciences	$6.93 +2.1%	2/14/2022	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy		Medium	View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022
FUSN Fusion Pharmaceuticals	$11.57 +2.2%	2/2/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Medium	View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 2/2/2022
ICCM IceCure Medical	$1.42 -0.7%	2/1/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low	View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022
DARE Daré Bioscience	$0.35 +0.8%	1/19/2022	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High	View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 1/19/2022
KYMR Kymera Therapeutics	$37.21 +9.5%	10/13/2021	Reiterated by	Brookline Capital Management	Analyst Leah Rush Cann	Buy	$80.00	Medium	View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021
FBRX Forte Biosciences	$0.63 +0.8%	9/3/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Hold		Low	View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021
VERU Veru	$0.38 -7.6%	8/27/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Medium	View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021
SCYX SCYNEXIS	$1.93 +0.3%	8/24/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low	View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021
CCCC C4 Therapeutics	$6.15 +9.4%	6/25/2021	Reiterated by	Brookline Capital Management	Analyst Leah Rush Cann	Buy		High	View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021
ATE Antibe Therapeutics	C$0.92 -3.2%	6/3/2021	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A	View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 6/3/2021
ATBPF Antibe Therapeutics	$0.67 -6.4%	6/3/2021	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Medium	View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021
BIOX Bioceres Crop Solutions	$13.57 +6.7%	5/7/2021	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A	View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021
SQZ SQZ Biotechnologies	$0.44 +61.1%	3/30/2021	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy		N/A	View details for Brookline Capital Management rating of SQZ Biotechnologies (NYSE:SQZ) on 3/30/2021
ONCT Oncternal Therapeutics	$9.88 +3.5%	3/30/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy	$320.00	High	View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 3/30/2021

MRNA Moderna	$87.41 -6.7%	2/26/2021	Target Raised by	Brookline Capital Management	-	Buy	$180.00 -> $205.00	Low	View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021
XFOR X4 Pharmaceuticals	$0.95 +10.0%	12/17/2020	Initiated by	Brookline Capital Management	Analyst L. Cann	Buy	$21.00	High	View details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020
VERU Veru	$0.38 -7.6%	12/14/2020	Target Raised by	Brookline Capital Management	Analyst K. Raja		$13.00 -> $17.00	High	View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020
SYRS Syros Pharmaceuticals	$7.07 +0.1%	11/10/2020	Initiated by	Brookline Capital Management	Analyst L. Cann	Buy	$190.00	Low	View details for Brookline Capital Management rating of Syros Pharmaceuticals (NASDAQ:SYRS) on 11/10/2020
ECOR electroCore	$7.35 +2.9%	10/23/2020	Initiated by	Brookline Capital Management	Analyst S. Yanchus	Buy	$75.00	Low	View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020
AWH Aspira Women's Health	$4.81 +3.0%	10/14/2020	Reiterated by	Brookline Capital Management	Analyst S. Yanchus	Buy		High	View details for Brookline Capital Management rating of Aspira Women’s Health (NASDAQ:AWH) on 10/14/2020
MEIP MEI Pharma	$4.78 +3.9%	10/12/2020	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy		Medium	View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 10/12/2020
DMTK DermTech	$1.25 +4.2%	9/11/2020	Initiated by	Brookline Capital Management	Analyst S. Yanchus	Buy		High	View details for Brookline Capital Management rating of DermTech (NASDAQ:DMTK) on 9/11/2020
FBRX Forte Biosciences	$0.63 +0.8%	8/28/2020	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$90.00	Low	View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020
HUGE FSD Pharma	$0.86 +3.6%	8/20/2020	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low	View details for Brookline Capital Management rating of FSD Pharma (NASDAQ:HUGE) on 8/20/2020
HUGE FSD Pharma	$0.86 +3.6%	8/20/2020	Initiated by	Brookline Capital Management	-	Buy	$11.00	N/A	View details for Brookline Capital Management rating of FSD Pharma (NASDAQ:HUGE) on 8/20/2020
KURA Kura Oncology	$19.97 -1.8%	8/16/2020	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy		Low	View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020
VERU Veru	$0.38 -7.6%	8/14/2020	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low	View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020
ARCT Arcturus Therapeutics	$39.64 +4.6%	8/11/2020	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low	View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020
ATE Antibe Therapeutics	C$0.92 -3.2%	7/15/2020	Reiterated by	Brookline Capital Management	Analyst S. Yanchus	Buy		N/A	View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 7/15/2020
MRNA Moderna	$87.41 -6.7%	7/13/2020	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy	$95.00	High	View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020
ASRT Assertio	$0.80 +1.0%	6/3/2020	Initiated by	Brookline Capital Management	-	Buy	$3.50	Low	View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020
OTLK Outlook Therapeutics	$0.41 -7.7%	5/5/2020	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy		High	View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 5/5/2020
DARE Daré Bioscience	$0.35 +0.8%	4/28/2020	Initiated by	Brookline Capital Management	Analyst S. Yanchus	Buy	$7.50	High	View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/28/2020
EDSA Edesa Biotech	$4.83 +3.4%	3/30/2020	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$70.00	High	View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020
CLPT ClearPoint Neuro	$7.29 +3.0%	3/11/2020	Reiterated by	Brookline Capital Management	Analyst S. Yanchus	Buy		High	View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020
ARMP Armata Pharmaceuticals	$3.83 -3.3%	3/13/2020	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High	View details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020
CLPT ClearPoint Neuro	$7.29 +3.0%	3/12/2020	Initiated by	Brookline Capital Management	-	Buy	$15.00	N/A	View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020
BIOX Bioceres Crop Solutions	$13.57 +6.7%	2/4/2020	Reiterated by	Brookline Capital Management	Analyst S. Yanchus	Buy		N/A	View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020
MDNA Medicenna Therapeutics	C$0.54 +14.9%	11/19/2019	Reiterated by	Brookline Capital Management	-	Buy	C$4.00	N/A	View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019
SCYX SCYNEXIS	$1.93 +0.3%	8/19/2019	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High	View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019
VXRT Vaxart	$1.19 +0.8%	8/15/2019	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$6.00	Low	View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019
VERU Veru	$0.38 -7.6%	7/29/2019	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$12.00	High	View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019
NHWK NightHawk Biosciences	$0.41 +9.0%	7/29/2019	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$56.00 -> $56.00	High	View details for Brookline Capital Management rating of NightHawk Biosciences (NYSE:NHWK) on 7/29/2019
CLRB Cellectar Biosciences	$3.50 -0.3%	7/29/2019	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$60.00 -> $60.00	High	View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/29/2019
ARCT Arcturus Therapeutics	$39.64 +4.6%	7/24/2019	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High	View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019
SCYX SCYNEXIS	$1.93 +0.3%	1/4/2019	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High	View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019
CLRB Cellectar Biosciences	$3.50 -0.3%	11/20/2018	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low	View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 11/20/2018
ARCT Arcturus Therapeutics	$39.64 +4.6%	9/27/2018	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low	View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018
NHWK NightHawk Biosciences	$0.41 +9.0%	8/1/2018	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low	View details for Brookline Capital Management rating of NightHawk Biosciences (NYSE:NHWK) on 8/1/2018

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:		2.8 out of 5 ( 2.8 of 5 stars)
Outperform Votes:		22,983 (Vote Outperform)
Underperform Votes:		17,843 (Vote Underperform)
Total Votes:		40,826

MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Stock Ratings Reports and Tools

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Ratings for Popular Stocks:

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Brookline Capital Management Analyst Recommendations & Stock Picks

MarketBeat Community Rating for Brookline Capital Management

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info